844-MY NK CELLScontact@nantkwest.com

      INVESTOR RELATIONS

      2015 News

      Keyword Search
       
      2017 | 2016 | 2015 | 2014
      DateTitle 
      12/22/15NantKwest to Host Investor Day on January 14, 2016
      CULVER CITY, Calif.--(BUSINESS WIRE)--Dec. 22, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, announced today that it will hold an R&D day on Thursday, January 14, 2016 at 12 p.m. PT in San Francisco, CA. The R&D Day will be hosted by key members of the ... 
      Printer Friendly Version
      12/18/15NantKwest Added to Nasdaq Biotechnology Index
      CULVER CITY, Calif.--(BUSINESS WIRE)--Dec. 18, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, today announced that it has been added to the NASDAQ Biotechnology Index® (NBI) as part of NBI’s annual selection of biotechnology and pharmaceutical companies listed on the ... 
      Printer Friendly Version
      12/09/15NantKwest Announces Presentation of Preclinical Data of HER2.taNK at the San Antonio Breast Cancer Symposium (SABCS)
      “Novel protocol combining metronomic Nant-paclitaxel with HER2-targeted natural killer cells (innate immunotherapy) for HER2-positive metastatic breast cancer” CULVER CITY, Calif.--(BUSINESS WIRE)--Dec. 9, 2015-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and infla... 
      Printer Friendly Version
      12/03/15NantKwest Announces Presentation at the American Society of Hematology (ASH) Annual Meeting; NK-92 Phase 1 Clinical Data on Dosing and Long-Term Survival in Relapsed Hematological Malignancies
      CULVER CITY, Calif.--(BUSINESS WIRE)--Dec. 3, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, today announced that the results of a Phase I clinical trial of NK-92 therapy will be presented at the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, to be ... 
      Printer Friendly Version
      11/17/15NantKwest Names Angela Wilson Chief Financial Officer
      CULVER CITY, Calif.--(BUSINESS WIRE)--Nov. 17, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, today announced the appointment of Angela Wilson as chief financial officer (CFO). She succeeds Richard Gomberg, who served as the company’s CFO since January 2010 as an independent... 
      Printer Friendly Version
      11/12/15NantKwest Announces $50 Million Stock Repurchase Program
      CULVER CITY, Calif.--(BUSINESS WIRE)--Nov. 12, 2015-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, announced today that its Board of Directors has authorized a stock repurchase program under which the company may repurchase up to $50 million of its ... 
      Printer Friendly Version
      11/02/15NantKwest Announces Presentations at Upcoming Investment Conference Meetings
      CULVER CITY, Calif.--(BUSINESS WIRE)--Nov. 2, 2015-- NantKwest Inc. (Nasdaq:NK) today announced that the company will be presenting at the following upcoming investment conferences in November and December: Citi 2015 Global Healthcare Conference, Jefferies 2015 Global Healthcare Conference and the Piper Jaffray 27th Annual Healthcare Conference. 2015 Citi Global Healthcare 1x1 Conference November 4-5, 2015, New York City, NY ... 
      Printer Friendly Version
      10/06/15NantKwest Continues the Strengthening of Its Leadership Team and Appoints a Seasoned Bioprocessing Manufacturing Executive
      Stephen Farrand, Ph.D., former Merck executive appointed Senior Vice President Global Manufacturing CULVER CITY, Calif.--(BUSINESS WIRE)--Oct. 6, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, today announced the appointment of Stephen Farrand, Ph. D., as senior v... 
      Printer Friendly Version
      09/22/15NantKwest Augments, Strengthens Senior Management Team
      --Company Adds Clinical Development, Medical Affairs and M&A Executives-- CULVER CITY, Calif.--(BUSINESS WIRE)--Sep. 22, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, today announced the appointments of three senior-level executives: Andreas Niethammer, M.D.,... 
      Printer Friendly Version
      08/26/15NantKwest Announces Prostate Cancer Foundation $1 Million Challenge Award to Study a Novel Natural Killer Cell Therapy in Prostate Cancer
      LOS ANGELES--(BUSINESS WIRE)--Aug. 26, 2015-- NantKwest (Nasdaq:NK), working with Ganesh Palapattu, MD and his team at the University of Michigan, along with Karen Knudsen, PhD and her group at Thomas Jefferson University, announced a $1 Million Challenge award from the Prostate Cancer Foundation to study NantKwest’s natural killer cell-based therapy as a novel therapeutic approach in advanced prostate cancer. The human immune system has a... 
      Printer Friendly Version
      07/31/15NantKwest Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
      CULVER CITY, Calif.--(BUSINESS WIRE)--Jul. 31, 2015-- NantKwest, Inc. (formerly Conkwest, Inc.) (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases, announced today the closing of its initial public offering of 9,531,200 shares of common stock at a price to the public of $25.00 per share, which inclu... 
      Printer Friendly Version
      07/28/15NantKwest Announces Pricing of Initial Public Offering
      CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (formerly Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases, announced today the pricing of its initial public offering of 8,288,000 shares of its common stock at a price to the public of $25.00 per share. All of the shares are being of... 
      Printer Friendly Version
      07/16/15NantKwest Announces Launch of Initial Public Offering
      CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (formerly known as Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the Natural Killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases, today announced that it has commenced an initial public offering of 7,000,000 shares of its common stock. The estimated price range of the common stock is between $20.00 and $23.00 per share. The underwriters ... 
      Printer Friendly Version
      06/19/15Conkwest Files Registration Statement for Proposed Initial Public Offering
      CARDIFF-BY-THE-SEA, Calif.--(BUSINESS WIRE)--Conkwest, Inc., a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of common stock to ... 
      Printer Friendly Version
      01/06/15Conkwest, Sorrento and NantWorks Announce Presentation at the 33rd Annual J. P. Morgan Healthcare Conference by Dr. Patrick Soon-Shiong
      SAN DIEGO, Jan. 6, 2015 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and Conkwest, Inc., an immuno-oncology company developing proprietary Neukoplast®, a Natural Killer (NK) cell-line based therapy, announced today that Dr. Patrick Soon-Shiong, NantWorks founder, physician scientist and biotechnology entrepreneur, is scheduled to present details about Conkwest's Neukoplast technology platform and the exclusive par... 
      Printer Friendly Version